- Home
- BIAF vs XTLB Comparison
BIAF vs XTLB Comparison
Compare BIAF & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- XTLB
- Stock Information
- Founded
- BIAF 2014
- XTLB 1993
- Country
- BIAF United States
- XTLB Israel
- Employees
- BIAF N/A
- XTLB N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- XTLB Health Care
- Exchange
- BIAF Nasdaq
- XTLB Nasdaq
- Market Cap
- BIAF 12.2M
- XTLB 10.4M
- IPO Year
- BIAF 2022
- XTLB 2005
- Fundamental
- Price
- BIAF $0.75
- XTLB $1.18
- Analyst Decision
- BIAF Hold
- XTLB
- Analyst Count
- BIAF 1
- XTLB 0
- Target Price
- BIAF N/A
- XTLB N/A
- AVG Volume (30 Days)
- BIAF 28.2M
- XTLB 4.8K
- Earning Date
- BIAF 05-14-2025
- XTLB 05-19-2025
- Dividend Yield
- BIAF N/A
- XTLB N/A
- EPS Growth
- BIAF N/A
- XTLB N/A
- EPS
- BIAF N/A
- XTLB N/A
- Revenue
- BIAF $9,362,022.00
- XTLB $46,000.00
- Revenue This Year
- BIAF $25.19
- XTLB N/A
- Revenue Next Year
- BIAF $20.00
- XTLB N/A
- P/E Ratio
- BIAF N/A
- XTLB N/A
- Revenue Growth
- BIAF 269.68
- XTLB N/A
- 52 Week Low
- BIAF $0.24
- XTLB $1.09
- 52 Week High
- BIAF $3.16
- XTLB $3.48
- Technical
- Relative Strength Index (RSI)
- BIAF 60.32
- XTLB 43.22
- Support Level
- BIAF $0.24
- XTLB $1.09
- Resistance Level
- BIAF $1.55
- XTLB $1.25
- Average True Range (ATR)
- BIAF 0.13
- XTLB 0.04
- MACD
- BIAF 0.08
- XTLB 0.02
- Stochastic Oscillator
- BIAF 38.64
- XTLB 42.11
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.